Infinity Pharmaceuticals Inc Quick Ratio (INFI) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Infinity Pharmaceuticals Inc   (NASDAQ: INFI)

Infinity Pharmaceuticals Inc 's Quick Ratio

INFI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2023, Quick Ratio deteriorated to 11.81 below Infinity Pharmaceuticals Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 110 other companies have achieved higher Quick Ratio than Infinity Pharmaceuticals Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 287 to 477.

Explain Quick Ratio?
How much Cash & cash equivalents INFI´s has?
What are INFI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INFI Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change -17.15 % -3.44 % -14.55 % 8.14 % 90.04 %
Y / Y Cash & cash equivalent Change -68.63 % -61.67 % -52.54 % -47.63 % -41.83 %
Quick Ratio MRQ 11.81 13.3 8.7 24.17 31.21
INFI's Total Ranking # 477 # 287 # 422 # 153 # 103
Seq. Current Liabilities Change -22.38 % -56.07 % 125.67 % 7.67 % -9.53 %
Seq. Cash & cash equivalent Change -31.05 % -32.82 % -18.8 % -16.6 % -15.74 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 111
Healthcare Sector # 181
Overall Market # 477


Quick Ratio Statistics
High Average Low
101.95 16.12 2.19
(Jun 30 2021)   (Sep 30 2015)




Financial Statements
Infinity Pharmaceuticals Inc 's Current Liabilities $ 2 Millions Visit INFI's Balance sheet
Infinity Pharmaceuticals Inc 's Cash & cash equivalent $ 18 Millions Visit INFI's Balance sheet
Source of INFI's Sales Visit INFI's Sales by Geography


Cumulative Infinity Pharmaceuticals Inc 's Quick Ratio

INFI's Quick Ratio for the trailling 12 Months

INFI Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -9.12 % 1.89 % 11.57 % 57.27 % 71.8 %
Y / Y Cash & cash equivalent TTM Growth -56.21 % -49.94 % -44.19 % -23.33 % 5.41 %
Quick Ratio TTM 13.17 16.61 20.56 23.03 27.33
Total Ranking TTM # 4290 # 1792 # 3367 # 690 # 3698
Seq. Current Liabilities TTM Growth -3.08 % -0.68 % -6.87 % 1.36 % 8.66 %
Seq. Cash & cash equivalent TTM Growth -23.14 % -19.79 % -16.86 % -14.57 % -12.14 %

Quick ratio ranking by company, industry and sector >> Back to INFI Financial Strength Comparisons >> Go to Compare INFI Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in INFI's Current Liabilities to $1.50 millions, cumulative Quick Ratio to 13.17 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 560 other companies have achieved higher Quick Ratio than Infinity Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 1792 to 4290.

Explain Quick Ratio?
How much Cash & cash equivalents INFI´s has?
What are INFI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 561
Healthcare Sector # 1122
Within the Market # 4290


trailing twelve months Quick Ratio Statistics
High Average Low
11.25 5.73 2.52
(Mar 31 2014)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Astria Therapeutics Inc   30.76 $ 202.958  Millions$ 6.598  Millions
Viking Therapeutics Inc   29.85 $ 392.920  Millions$ 13.164  Millions
Adc Therapeutics Sa  29.72 $ 347.510  Millions$ 11.691  Millions
Akero Therapeutics Inc   29.60 $ 639.444  Millions$ 21.602  Millions
Atossa Therapeutics Inc   28.61 $ 99.500  Millions$ 3.478  Millions
Climb Bio Inc   28.37 $ 102.633  Millions$ 3.618  Millions
Minerva Neurosciences Inc   27.15 $ 51.797  Millions$ 1.908  Millions
Theseus Pharmaceuticals Inc   27.10 $ 208.205  Millions$ 7.682  Millions
Verona Pharma Plc  26.02 $ 270.727  Millions$ 10.404  Millions
Dice Therapeutics Inc   25.69 $ 528.383  Millions$ 20.571  Millions
Ars Pharmaceuticals Inc   25.09 $ 252.208  Millions$ 10.054  Millions
Arca Biopharma Inc  25.07 $ 40.156  Millions$ 1.602  Millions
Design Therapeutics Inc   24.98 $ 303.088  Millions$ 12.133  Millions
Aprea Therapeutics Inc   24.47 $ 27.685  Millions$ 1.131  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Bright Minds Biosciences Inc   24.16 $ 5.197  Millions$ 0.215  Millions
Stoke Therapeutics Inc   24.07 $ 231.447  Millions$ 9.615  Millions
Eqrx Inc   23.19 $ 1,261.556  Millions$ 54.394  Millions
Cocrystal Pharma Inc   22.81 $ 32.419  Millions$ 1.421  Millions
Kura Oncology Inc   22.13 $ 476.979  Millions$ 21.554  Millions
Innoviva Inc   21.67 $ 291.956  Millions$ 13.474  Millions
Diamedica Therapeutics Inc   21.62 $ 40.368  Millions$ 1.867  Millions
Edgewise Therapeutics inc   21.52 $ 309.928  Millions$ 14.400  Millions
Acrivon Therapeutics Inc   21.51 $ 150.954  Millions$ 7.017  Millions
Immuneering Corporation  21.18 $ 108.985  Millions$ 5.146  Millions
Nuvalent Inc   20.74 $ 431.239  Millions$ 20.795  Millions
Cyteir Therapeutics Inc   20.31 $ 133.635  Millions$ 6.579  Millions
Terns Pharmaceuticals Inc   20.06 $ 285.603  Millions$ 14.238  Millions
Keros Therapeutics Inc   20.01 $ 322.026  Millions$ 16.095  Millions
Trevi Therapeutics Inc   19.99 $ 94.152  Millions$ 4.711  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.